Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize increased disease-associated polyamines using complementary pharmacotherapies. The company’s lead assets are ivospemin (SBP-101), CPP-1X, utilized alone or in combination with Sulindac (Flynpovi™) which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.